1.Patients’ and caregivers’ perception of safety and accessibility of cancer care during the covid-19 pandemic: A survey in a tertiary academic cancer center in the Philippines
Luisa E. Jacomina ; Imee Loren C. Lim ; Eugene Richard T. Yap ; Kelvin Ken L. Yu ; Lester Bryan A. Co ; Julie Ann R. Tapispisan ; Jayson L. Co ; Warren R. Bacorro ; Michael Benedict A. Mejia ; Teresa T. Sy Ortin
Journal of Medicine University of Santo Tomas 2023;7(1):1071-1079
Background:
The COVID-19 pandemic has caused a global public health emergency. High levels of fear and limited access to cancer treatment may jeopardize the delivery of optimal oncologic care, potentially influencing treatment outcomes. This study aimed to identify patients’ and their caregivers’ perception of safety and accessibility of cancer care during the COVID-19 pandemic.
Methods:
A cross-sectional survey of patients and caregivers at the Benavides Cancer Institute, University of Santo Tomas Hospital was performed from August to October 2020 using a 20-item investigator-developed questionnaire.
Results:
A total of 207 participants answered the survey. Frequency of hospital visits varied from none to more than ten times in the previous month; but having multiple postponements were uncommon. Eighty-two percent, 77%, 62%, and 55% of participants reported being afraid of contracting COVID-19 from other patients, hospital surroundings, hospital staff, and doctors, respectively. Twenty-six percent and 12% had difficulty finding transportation and passing through checkpoints, respectively. Twenty-eight percent strongly expressed financial limitations in prioritizing cancer care. Participants were amenable to the use of telemedicine and stringent protocols to reduce in-hospital transmission risk, but had some reluctance to spend out of their pockets for screening tests.
Conclusion
The perceived safety of cancer care was influenced by fears of contracting COVID-19; and accessibility was influenced by limited transportation and financial constraints. Despite these, multiple postponements and cancelled hospital visits were uncommon. Institutional approaches targeting these concerns will be crucial to ensure safe and timely delivery of cancer care during the COVID-19 pandemic and further mitigate its impact on oncologic outcomes.
COVID-19
;
Pandemics
;
Safety
2.A dosimetric analysis of incidental radiation to the internal mammary nodes with a three-field chest wall technique.
Ryan Anthony F. AGAS ; Lester Bryan A. CO ; Maureen R. BOJADOR ; Mario B. SARMIENTO ; Luisa E. JACOMINA ; Kathleen H. BALDIVIA
Journal of Medicine University of Santo Tomas 2021;5(2):774-782
Objectives: The authors' aim was to conduct a dosimetric analysis of the incidental radiation dose to the internal mammary node (IMN) region using a three-field chest wall technique (TFCWT).
Methods: This retrospective study utilized 3D-conformal radiotherapy plans of 50 postmastectomy patients (25 left-sided and 25 rightsided). All plans used the TFCWT, composed of narrowed tangents matched medially to an AP electron field, and prescribed a total dose of 50 Gy in 28 fractions. The IMNs were not intentionally treated in all included plans.
Results: The mean dose to the IMN-planning target volume (IMN-PTV) was 45.1 Gy (26.4 - 55.6, SD 6.5). Minimum doses received by 95% and 90% of the IMN-PTV were 29.3 Gy (8 - 49, SD 10.0) and 34.0 Gy (10.0 - 52.0, SD 8.6), respectively. The percent volume of IMN-PTV receiving 100%, 95%, 90%, and 80% were 47.4% (3 - 94, SD 21.6), 55.6% (6 - 97, SD 22.4), 61.92% (7 - 98, SD 22.2), and 72.61% (18-100, SD 20.2), respectively. The average ipsilateral lung V20 Gy (with supraclavicular fields) was 25.0% (16 - 29, SD 3.4), and the average heart mean dose was 2.5 Gy (0.5 - 7.9, SD 1.58).
Conclusion: Although the results suggest increased IMN radiation doses with the TFCWT when compared historically to standard tangents, the incidental doses are comparatively less than that traditionally prescribed to the IMNs in high-risk patients. It is unknown whether this incidental IMN dose confers any clinical benefit.
Breast Neoplasms